AR039915A1 - Tratamiento de la hepatitis c en la poblacion asiatica - Google Patents

Tratamiento de la hepatitis c en la poblacion asiatica

Info

Publication number
AR039915A1
AR039915A1 ARP030101903A ARP030101903A AR039915A1 AR 039915 A1 AR039915 A1 AR 039915A1 AR P030101903 A ARP030101903 A AR P030101903A AR P030101903 A ARP030101903 A AR P030101903A AR 039915 A1 AR039915 A1 AR 039915A1
Authority
AR
Argentina
Prior art keywords
treatment
hepatitis
asian population
beta
ifn
Prior art date
Application number
ARP030101903A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR039915A1 publication Critical patent/AR039915A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Uso del IFN-beta recombinante para la elaboración de un medicamento para el tratamiento de la hepatitis C por vía subcutánea a pacientes de raza asiática que no respondieron a tratamientos previos con interferón-alfa. De acuerdo con la realización preferida de la presente, este tratamiento puede ser dirigido a aquellos pacientes que después de 4 semanas iniciales de tratamiento con IFN-beta logran depuración de ARN del VHC.
ARP030101903A 2002-06-03 2003-05-29 Tratamiento de la hepatitis c en la poblacion asiatica AR039915A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02100632 2002-06-03

Publications (1)

Publication Number Publication Date
AR039915A1 true AR039915A1 (es) 2005-03-09

Family

ID=29595047

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101903A AR039915A1 (es) 2002-06-03 2003-05-29 Tratamiento de la hepatitis c en la poblacion asiatica

Country Status (21)

Country Link
US (1) US7344709B2 (es)
EP (1) EP1509242A1 (es)
JP (1) JP2005533035A (es)
KR (1) KR20050008762A (es)
CN (1) CN1671408A (es)
AR (1) AR039915A1 (es)
AU (1) AU2003250231B2 (es)
BR (1) BR0311696A (es)
CA (1) CA2487299A1 (es)
EA (1) EA007091B1 (es)
HR (1) HRP20041076A2 (es)
IL (1) IL165521A (es)
MX (1) MXPA04012043A (es)
MY (1) MY139068A (es)
NO (1) NO20045579L (es)
PL (1) PL374578A1 (es)
RS (1) RS105104A (es)
TW (1) TWI334785B (es)
UA (1) UA79615C2 (es)
WO (1) WO2003101478A1 (es)
ZA (1) ZA200409218B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
WO2009069682A1 (ja) * 2007-11-28 2009-06-04 Toray Industries, Inc. 肝炎の治療剤又は予防剤
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition
ES2527510T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Métodos para el tratamiento del VHC que comprenden al menos dos agentes antivirales de acción directa, ribavirina pero no interferón
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012003457T5 (de) 2011-10-21 2015-03-12 Abbvie Inc. Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN102538594B (zh) * 2012-01-10 2013-12-25 西安工业大学 交汇式激光精度靶及其测试方法
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) * 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
PT1075281E (pt) 1998-04-28 2004-11-30 Applied Research Systems Conjugados poliol-ifn-beta

Also Published As

Publication number Publication date
NO20045579L (no) 2005-01-26
EP1509242A1 (en) 2005-03-02
RS105104A (en) 2007-02-05
BR0311696A (pt) 2005-03-22
JP2005533035A (ja) 2005-11-04
PL374578A1 (en) 2005-10-31
ZA200409218B (en) 2006-02-22
MXPA04012043A (es) 2005-03-07
WO2003101478A1 (en) 2003-12-11
IL165521A0 (en) 2006-01-15
US20060029572A1 (en) 2006-02-09
HRP20041076A2 (en) 2005-02-28
IL165521A (en) 2010-05-17
KR20050008762A (ko) 2005-01-21
AU2003250231A1 (en) 2003-12-19
AU2003250231B2 (en) 2009-01-08
CN1671408A (zh) 2005-09-21
CA2487299A1 (en) 2003-12-11
US7344709B2 (en) 2008-03-18
TW200407159A (en) 2004-05-16
TWI334785B (en) 2010-12-21
MY139068A (en) 2009-08-28
EA007091B1 (ru) 2006-06-30
UA79615C2 (en) 2007-07-10
EA200401618A1 (ru) 2005-06-30

Similar Documents

Publication Publication Date Title
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
ATE497775T1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
HUP0003384A2 (hu) Legalább egy, kettős szálú RNS és legalább egy, vírus elleni szer kombinációját tartalmazó termék
HK1084862A1 (en) Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject
AR052165A1 (es) Tratamiento de hepatitis c en la poblacion asiatica
AR023824A1 (es) Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado.
AR039915A1 (es) Tratamiento de la hepatitis c en la poblacion asiatica
UY28080A1 (es) Isómeros posicionales del ifn peg alfa 2a
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
MD2549F1 (en) Method of treatment of the chronic viral hepatitis C
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
CO5160259A1 (es) Interferon alfa pegilado en la terapia contra el hiv
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
SG165996A1 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
BRPI0406985A (pt) Terapia de combinação de hcv
AU8353601A (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
James Ribavirin approved for hepatitis C combination treatment
BR112022006913A2 (pt) Métodos para tratar infecções virais de hepatite delta
Klein Does your liver quiver? Hepatitis C and HIV
AR013498A1 (es) Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa
HK1056117A1 (en) Treatment of hepatitis C with thymosin and pegylated interferon
BR0213554A (pt) Timosina para aumento da imunização genética
ITPE920003A1 (it) Poltrona sdraio fisioterapico.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal